AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32370582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults living in households where decision making is shared between couples
Number of subjects: 809
Study 35010328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group in neutral location
Number of subjects: 268
Study 35010328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group in contextualized location
Number of subjects: 268
Study 35010328 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet)
Number of subjects: 268
Study 35010328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (neutral and contextualized)
Number of subjects: 268
Study 33322686 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus community-level intervention delivered by local AN 'Native Sisters'
Number of subjects: 352
Study 33322686 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 352
Study 34785236 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg, once daily)
Number of subjects: 49
Study 34785236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to prescribed medications
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to diet plans
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged (50–64 years)
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microvascular complications
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of diabetes (>15 years)
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia
Number of subjects: 1146
Study 33242515 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age group (35–49 years vs. >64 years)
Number of subjects: 1146
Study 32762226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase treatment in patients with low coagulation index (CI)
Number of subjects: 43
Study 32762226 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal coagulation index (CI)
Number of subjects: 43
Study 35525415 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality training system (AR group)
Number of subjects: 38
Study 35525415 — intervention group
Group type: COMPARATOR
Intervention: Instructional video (video group)
Number of subjects: 38
Study 35525415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AR and video)
Number of subjects: 38
Study 32897569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1 g intravenous initially, then every 6 months for 12 months
Number of subjects: 84
Study 32897569 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) 40 mg subcutaneously 3 times/week for 12 months
Number of subjects: 84
Study 36476684 — intervention group
Group type: EXPERIMENTAL
Intervention: Translucent zirconia (4Y-PSZ) restorations
Number of subjects: 44
Study 36476684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate ceramic restorations (LD)
Number of subjects: 44
Study 36476684 — intervention group
Group type: COMPARATOR
Intervention: Bi-layered zirconia restorations (BL)
Number of subjects: 44
Study 36476684 — intervention group
Group type: COMPARATOR
Intervention: Dispersed nanoparticle-filled composite resin restorations (CM)
Number of subjects: 44
Study 33435932 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 30245
Study 33435932 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with disordered eating behaviors
Number of subjects: 30245
Study 33435932 — intervention group
Group type: COMPARATOR
Intervention: Alcohol use
Number of subjects: 30245
Study 33435932 — intervention group
Group type: COMPARATOR
Intervention: Sunbed use
Number of subjects: 30245
Study 33435932 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 30245
Study 33435932 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss‐of‐control eating
Number of subjects: 30245
Study 32410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Care availability for perinatal depression at the primary care level
Number of subjects: 42
Study 32410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health benefits of treatment for perinatal depression
Number of subjects: 42
Study 32410586 — intervention group
Group type: COMPARATOR
Intervention: Stigma and negative stereotypes expressed by care providers
Number of subjects: 42
Study 32410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient resilience
Number of subjects: 42
Study 32410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Providers trained in management of perinatal depression
Number of subjects: 42
Study 32410586 — intervention group
Group type: COMPARATOR
Intervention: Unsupportive and stigmatizing clinic environments
Number of subjects: 42
Study 32410586 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce stigma among healthcare providers
Number of subjects: 42
Study 36964526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study 33476048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 16
Study 33476048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32826784 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (2× weekly, 60-minute sessions for 12 weeks)
Number of subjects: 150
Study 32826784 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 150
Study 32826784 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 150
Study 34657138 — intervention group
Group type: EXPERIMENTAL
Intervention: AGMG0201 (active study drug)
Number of subjects: 24
Study 34657138 — intervention group
Group type: EXPERIMENTAL
Intervention: AGMG0201 (high-dose group)
Number of subjects: 24
Study 34657138 — intervention group
Group type: EXPERIMENTAL
Intervention: AGMG0201 (low-dose group)
Number of subjects: 24
Study 34657138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33024120 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics + Berberine (BBR)
Number of subjects: 409
Study 33024120 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR) alone
Number of subjects: 409
Study 33024120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 33024120 — intervention group
Group type: COMPARATOR
Intervention: Probiotics alone
Number of subjects: 409
Study 35470006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric heating moxibustion (EM)
Number of subjects: 40
Study 35470006 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (AC)
Number of subjects: 40
Study 34062976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aguamiel-based beverage fermented with Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus brevis (100 mL, 3 × 10^8 cfu/mL) for 8 weeks
Number of subjects: 27
Study 34062976 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo intervention)
Number of subjects: 27
Study 33986484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Practicality Index (DPI) training
Number of subjects: 108
Study 33986484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DPI training)
Number of subjects: 108
Study 32860109 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP (piperacillin/tazobactam)
Number of subjects: 90
Study 32860109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32860109 — intervention group
Group type: COMPARATOR
Intervention: PAP and Placebo
Number of subjects: 90
Study 35430800 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise rehabilitation guided by 6-minute walk test (6-MWT) for 12 weeks
Number of subjects: 100
Study 35430800 — intervention group
Group type: COMPARATOR
Intervention: No exercise rehabilitation
Number of subjects: 100
Study 33534134 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE)
Number of subjects: 45
Study 32784847 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation
Number of subjects: 92
Study 32784847 — intervention group
Group type: COMPARATOR
Intervention: Pea protein supplementation
Number of subjects: 92
Study 32784847 — intervention group
Group type: COMPARATOR
Intervention: Whey protein vs Pea protein
Number of subjects: 92
Study 32784847 — intervention group
Group type: COMPARATOR
Intervention: Whey and Pea protein vs Water supplementation
Number of subjects: 92
Study 33119924 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief/habit drinkers
Number of subjects: 184
Study 33119924 — intervention group
Group type: COMPARATOR
Intervention: Reward drinkers
Number of subjects: 184
Study 32362132 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance intervention (10-week, two times weekly progressive balance training led by physical therapists)
Number of subjects: 117
Study 32362132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 117
Study 32362132 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance intervention
Number of subjects: 117
Study 35623183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled nitric oxide (iNO) at 250 ppm for 30 minutes
Number of subjects: 47
Study 35623183 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (control group)
Number of subjects: 47
Study 33730350 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 33730350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential afatinib followed by osimertinib
Number of subjects: 0
Study 35184413 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 17
Study 35184413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of apatinib and melittin
Number of subjects: 17
Study 35184413 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib and melittin
Number of subjects: 17
Study 34191841 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved choice experiment method for soil fertility management technologies
Number of subjects: 962
Study 35050320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg or 10 mg/kg every 2 or 3 weeks)
Number of subjects: 575
Study 35050320 — intervention group
Group type: COMPARATOR
Intervention: Standard method (Response Evaluation Criteria in Solid Tumors 1.1)
Number of subjects: 575
Study 33602745 — intervention group
Group type: EXPERIMENTAL
Intervention: DISORDER motion correction
Number of subjects: 32
Study 2010154965 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BTIs)
Number of subjects: 15
Study 35504809 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness-based protocol for imaging (intervention cohort)
Number of subjects: 455
Study 35504809 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging protocol (baseline cohort)
Number of subjects: 455
Study 34618311 — intervention group
Group type: EXPERIMENTAL
Intervention: Thula Baba Box (TBB) and community health worker (CHW) programme
Number of subjects: 72
Study 34618311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 35368773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Bushen acupuncture, intradermal acupuncture, and moxibustion integrated therapy combined with core muscle training program (CMT)
Number of subjects: 120
Study 35368773 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture combined with the CMT
Number of subjects: 120
Study 32063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in total physical activity (PA)
Number of subjects: 489
Study 32063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in moderate physical activity
Number of subjects: 489
Study 32063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in moderate-to-vigorous physical activity
Number of subjects: 489
Study 35792788 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine toothpaste
Number of subjects: 72
Study 35792788 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride toothpaste
Number of subjects: 72
Study 34518159 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAL-D (culturally tailored T2D self-management education and support program); 7 sessions, 14 hours of group-based education, behavior change support, and supervised physical activity.
Number of subjects: 55
Study 34518159 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 55
Study 33482385 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised at-home cardiovascular exercise program for 6 months
Number of subjects: 77
Study 33482385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 32608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation (EMN) for cup placement at predetermined angles (inclination: 42.5°; anteversion: 15°)
Number of subjects: 84
Study 32608315 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique for cup placement aiming at the same target angles
Number of subjects: 84
Study 32608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation (EMN)
Number of subjects: 84
Study 32608315 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 84
Study 32608315 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation (EMN) and Freehand technique
Number of subjects: 84
Study 36177926 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoqinglong Decoction (1 000 mg/L)
Number of subjects: 0
Study 36177926 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingqi Huatan Pill (1 000 mg/L)
Number of subjects: 0
Study 36177926 — intervention group
Group type: EXPERIMENTAL
Intervention: PDTC (100 μmol/L)
Number of subjects: 0
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as LSF, single oral administration of 20 mg
Number of subjects: 103
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as LSF, multiple oral administration over 10 days at 5 mg once daily and 10 mg once daily and 10 mg twice daily
Number of subjects: 103
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as IR tablet, 5 or 20 mg
Number of subjects: 103
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as LSF, doses from 1 to 40 mg
Number of subjects: 103
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as LSF
Number of subjects: 103
Study 33759250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside as LSF, fed state
Number of subjects: 103
Study 32201234 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks for up to 12 months)
Number of subjects: 595
Study 32201234 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 595
Study 32201234 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab (12 weeks durvalumab 20 mg/kg + tremelimumab 1 mg/kg q4w then 34 weeks durvalumab 10 mg/kg q2w)
Number of subjects: 595
Study 32201234 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 595
Study 35734420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 49
Study 35734420 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative yoga
Number of subjects: 49
Study 35734420 — intervention group
Group type: COMPARATOR
Intervention: Both yoga interventions
Number of subjects: 49
Study 33289149 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative decrease of albumin (ΔAlb) calculated on postoperative day 1, with a cut-off established at 11 g/L.
Number of subjects: 1046
Study 33289149 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI and laparoscopy as factors associated with lower ΔAlb.
Number of subjects: 1046
Study 36344108 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC and lung ultrasound-guided decongestion therapy
Number of subjects: 58
Study 36344108 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guided decongestion therapy
Number of subjects: 58
Study 33063862 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 2886
Study 33063862 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 2886
Study 33063862 — intervention group
Group type: COMPARATOR
Intervention: Galcanezumab
Number of subjects: 2886
Study 35420245 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (supportive counseling and facilitated referrals)
Number of subjects: 140
Study 33928857 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection (CI)
Number of subjects: 83
Study 33928857 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Release of the A1 Pulley (PTFR)
Number of subjects: 83
Study 35302400 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance/resistance exercise for 24 weeks
Number of subjects: 49
Study 33709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care model (CCM) lifestyle intervention over 4 months
Number of subjects: 50
Study 34637505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein milk-cereal mix (5.6 g protein, PER: 18%, 1.68 g from milk source)
Number of subjects: 1548
Study 34637505 — intervention group
Group type: COMPARATOR
Intervention: Modest-protein milk-cereal mix (2.5 g protein, PER: 8%; 0.75 g from milk source)
Number of subjects: 1548
Study 34423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration (50 Hz, 10 min/day for 12 weeks)
Number of subjects: 20
Study 34423388 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study 34423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Force application
Number of subjects: 20
Study 34423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 20
Study 32390309 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Benzoyl Peroxide (BPO), twice a day
Number of subjects: 90
Study 32390309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5% BPO + 3% Erythromycin, twice a day
Number of subjects: 90
Study 32390309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 4% Niacinamide + 1% Gallic Acid + 1% Lauric Acid, twice a day
Number of subjects: 90
Study 36303217 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid social media recruitment methods (no financial cost)
Number of subjects: 296
Study 36303217 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid Facebook advertisements (£259.93 total cost, £2.11 per participant)
Number of subjects: 296
Study 36303217 — intervention group
Group type: EXPERIMENTAL
Intervention: Other recruitment methods
Number of subjects: 296
Study 33147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 80
Study 33147332 — intervention group
Group type: COMPARATOR
Intervention: Conventional hepatectomy
Number of subjects: 80
Study 33147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of CTC
Number of subjects: 80
Study 33147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 80
Study 33147332 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 80
Study 32792431 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis (2 days a week)
Number of subjects: 54
Study 32792431 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (3 times a week)
Number of subjects: 54
Study 32792431 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Number of subjects: 54
Study 32792431 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis
Number of subjects: 54
Study 35931964 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program based on Health Belief Model (HBM)
Number of subjects: 146
Study 35931964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study 36376310 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac at a 10-month interval (cohort 1)
Number of subjects: 384
Study 36376310 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac at a 12-month interval (cohort 2)
Number of subjects: 384
Study 36376310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 384
Study 34756882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 303
Study 34756882 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg
Number of subjects: 303
Study 35854358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h music listening sessions twice daily through noise-canceling headphones
Number of subjects: 160
Study 35854358 — intervention group
Group type: COMPARATOR
Intervention: 1-h sessions of a silence track twice daily through noise-canceling headphones
Number of subjects: 160
Study 35854358 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 160
Study 35854358 — intervention group
Group type: COMPARATOR
Intervention: Silence track attention control
Number of subjects: 160
Study 35854358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after hospital discharge
Number of subjects: 160
Study 33737417 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKRS) within 2 months following randomisation
Number of subjects: 100
Study 33737417 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 100
Study 33737417 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKRS)
Number of subjects: 100
Study 34145042 — intervention group
Group type: EXPERIMENTAL
Intervention: FICare
Number of subjects: 455
Study 34956191 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-IM
Number of subjects: 97
Study 34956191 — intervention group
Group type: COMPARATOR
Intervention: NET-EN
Number of subjects: 97